Defilade Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Defilade Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Buy	+3,670,135	New	+$14.6M	1.5%	27

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Defilade Capital Management's LRMR Position: Q2 2026 in Review

Defilade Capital Management opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 3,670,135 shares worth $11.2M. The stake represents 1.5% of the portfolio and ranks #27 among its holdings.

161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Defilade Capital Management held 3,670,135 shares of Larimar Therapeutics worth $11.2M as of Q2 2026.
Larimar Therapeutics was a new Defilade Capital Management position in Q2 2026.
Larimar Therapeutics made up 1.5% of Defilade Capital Management's portfolio in Q2 2026, its #27 holding.
161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.